Cramer was conservative when he said the share price will double from 60 area. Kalydeco alone can address 15% of CF patients eventually. Within 1.5 years Kalydeco will be used among about 10% of patients (551, R117H, and gating mutations). The 10% of 70,000 in the US and EU will be 7000, and even if it is discounted by 30% in the US, EU, and UK, the revenue from Kalydeco alone support a 15 B market cap. When VX-809 is approved to be used along with Kalydeco for patients with F508del, 35,000 CFers will benefit, and even if VX-809 is distributed free of charge, the Kalydeco sales alone will quintuple. It is only a matter of time that the correctors ( VX-809, 661 or any others) will become potent and safe enough to benefit a majority of CFers. All of 508 CFers will need a potentiator (=Kalydeco) in addition to a corrector(s).
On 10-13--12 you posted :
"For those who bought shares on Cramer's suggestion, I have to tell you that Cramer was correct. He was rather conservative in saying that the pps would double. It will more than double from here in two years. Cramer assumed that the drug price would be 200 K. To treat homozygous 508 patients, two drugs are needed, VX-809 and Kalydeco. Kalydeco alone costs almost 300 K now." I might as well assume from your statements that you are picking up cheaper shares here in the low 40's or are you concerned about the latest poor earnings report caring over into the next few quarters as well as their burn rate?